Viking Therapeutics Inc. (VKTX)

8.62
NASDAQ : Health Technology
Prev Close 8.50
Day Low/High 8.32 / 8.73
52 Wk Low/High 3.69 / 24.00
Avg Volume 2.92M
Exchange NASDAQ
Shares Outstanding 71.99M
Market Cap 611.88M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Viking Therapeutics To Report Financial Results For Fourth Quarter And Year-End 2018 On March 13, 2019

Viking Therapeutics To Report Financial Results For Fourth Quarter And Year-End 2018 On March 13, 2019

Conference Call Scheduled for Wednesday, March 13 at 4:30 p.m. Eastern Time

Viking Therapeutics To Participate In Upcoming Investor Conferences And Events

Viking Therapeutics To Participate In Upcoming Investor Conferences And Events

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Viking Therapeutics, Inc.

First Week Of March 15th Options Trading For Viking Therapeutics (VKTX)

First Week Of March 15th Options Trading For Viking Therapeutics (VKTX)

Investors in Viking Therapeutics Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VKTX options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

Interesting VKTX Put And Call Options For January 2021

Interesting VKTX Put And Call Options For January 2021

Investors in Viking Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 717 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Viking Therapeutics To Present At Biotech Showcase 2019

Viking Therapeutics To Present At Biotech Showcase 2019

SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

Oversold Conditions For Viking Therapeutics (VKTX)

Oversold Conditions For Viking Therapeutics (VKTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

VKTX: Insiders Vs. Shorts

VKTX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Viking Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 7.60 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Viking Therapeutics Shows How Quickly This Market Can Turn

Viking Therapeutics Shows How Quickly This Market Can Turn

If you are trying to pick stocks for the longer term it can be quite challenging right now.

Viking Therapeutics Presents Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol In Oral Late-Breaker Presentation At The Liver Meeting® 2018

Viking Therapeutics Presents Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol In Oral Late-Breaker Presentation At The Liver Meeting® 2018

Study Achieves Primary Endpoint, Demonstrating Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at Week 12

Viking Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Viking Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

This Is Not Just a Market of Oversold Bounces Now

This Is Not Just a Market of Oversold Bounces Now

What is most interesting about the action today is a spike in the speculative action.

Viking Therapeutics To Report Financial Results For Third Quarter 2018 On November 7, 2018

Viking Therapeutics To Report Financial Results For Third Quarter 2018 On November 7, 2018

Conference Call Scheduled for Wednesday, November 7 at 4:30 p.m. Eastern Time

My Stock of the Week: ENDRA Life Sciences

My Stock of the Week: ENDRA Life Sciences

I'm simply focusing on individual stocks at this point and am not too concerned about the macro picture.

It Was a Very Rough Week

It Was a Very Rough Week

Just when you thought the worst was over another wave of selling would hit.

Is the Market Washed Out and Ready for Another Upcycle?

Is the Market Washed Out and Ready for Another Upcycle?

One very encouraging sign Friday is relative outperformance by names that have lately been the weakest.

CAT Stock Gets Thrown Into the Dumpster

CAT Stock Gets Thrown Into the Dumpster

This stock can become much cheaper if there is a major cycle turn occurring.

6 Steps for Dealing With a Market That Can't Be Trusted

6 Steps for Dealing With a Market That Can't Be Trusted

They include holding a high level of cash, keeping stops tight and being patient.

Netflix Is Tonight's Big Report: Here's How I Would Play It

Netflix Is Tonight's Big Report: Here's How I Would Play It

This is a battleground stock that has made big moves in both directions on earnings in the past.

Square Continues to See Extreme Pressure

Square Continues to See Extreme Pressure

If you are interested in Square longer term be patient and wait for the drama to end.

Viking Therapeutics Announces Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session Of The 88th Annual Meeting Of American Thyroid Association (ATA)

Viking Therapeutics Announces Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session Of The 88th Annual Meeting Of American Thyroid Association (ATA)

VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia)

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol

There's Nothing Very Attractive About GE

There's Nothing Very Attractive About GE

It's an interesting story but there are better places for your funds.

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211

Viking Therapeutics To Participate In Upcoming Investor Conferences

Viking Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

FedEx's Report Was Soft, but the Guidance Isn't Bad

FedEx's Report Was Soft, but the Guidance Isn't Bad

It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.